A checklist of best practices for mid-life products a few years after launch to help companies with growing oncology portfolios determine not only to see if there’s hidden vitality still left in their aging brands.
Bob Josefsberg
Advertisement
Articles by Bob Josefsberg
Advertisement
Latest Updated Articles
Making the Most of Maturing Oncology BrandsPublished: May 30th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Novo Nordisk's Shares Fall After Board Shake-Up
2
Roundup: Pharma Industry Raises Funding Aimed at Advancing the Development and Testing of Rare Disease Treatments
3
Moderna Ceases Development of mRNA-1647 After Failing to Reach Primary Goal in Clinical Trial
4
Novo Nordisk Stock Reacts to Recent Board Changes
5
